Society

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Retrieved on: 
Wednesday, April 24, 2024
CGEM, ASCO, MBA, NKG2D, Annual general meeting, MICA, MPH, Therapy, Patient, Society, MICB, Vaccine

The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.

Key Points: 
  • The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.
  • “We are pleased to present our initial clinical findings for CLN-619 plus pembrolizumab in patients with solid tumors at ASCO 2024, along with updated results from our monotherapy dose escalation study.
  • CLN-619 is a novel, potential first-in-class antibody that binds to MICA and MICB stress-induced ligands that engage the activating receptor NKG2D, present on both innate and adaptive immune cells.
  • The details of the presentation include:
    Poster Title: CLN-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab for advanced solid tumors: Updated results of a Ph1 study

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

Retrieved on: 
Wednesday, April 24, 2024
CD3, Cancer, GITR, Multiple myeloma, Safety, Regeneron Pharmaceuticals, Monoclonal antibody, ASCO, CD28, Lymphoma, Patient, Society, Melanoma, Head, Annual general meeting, Pharmaceutical industry

TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology pipeline will be shared across 17 presentations at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May 31 to June 5 in Chicago, IL. Notably, new safety and efficacy results from a Phase 1/2 trial investigating the costimulatory bispecific antibody REGN7075 (EGFRxCD28) in combination with Libtayo in patients with certain advanced solid tumors will be featured in an oral presentation.

Key Points: 
  • Notably, new safety and efficacy results from a Phase 1/2 trial investigating the costimulatory bispecific antibody REGN7075 (EGFRxCD28) in combination with Libtayo in patients with certain advanced solid tumors will be featured in an oral presentation.
  • “The breadth of our presentations at ASCO showcase our progress in advancing multiple promising and distinct investigational treatment approaches for a diverse array of difficult-to-treat cancers,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron.
  • “These latest clinical results build on our ongoing commitment to cancer research and reflect our focus on advancing a pipeline of internally-developed candidates that have the potential to offer novel and differentiated therapies.
  • Among them are presentations on updated data and new analyses for linvoseltamab (BCMAxCD3) in multiple myeloma; odronextamab (CD20xCD3) in several lymphoma subtypes; REGN6569 (GITR) in combination with Libtayo across solid tumors; and fianlimab (LAG-3 inhibitor) in combination with Libtayo in non-small cell lung cancer, melanoma and head and neck cancer.

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Cure, Safety, Tumor microenvironment, Intelligence, PDAC, ASCO, Merck & Co., Society, Poster, Annual general meeting, Therapy, Merck, Pharmaceutical industry

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that a late-breaking abstract with preliminary findings from the Phase 2 investigator-sponsored trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) has been selected for presentation in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from May 31 to June 4, 2024 in Chicago, IL.

Key Points: 
  • The meeting will take place from May 31 to June 4, 2024 in Chicago, IL.
  • On February 6, 2024, BioXcel Therapeutics announced the completion of patient enrollment in the safety lead-in portion of the trial.
  • Through its OnkosXcel Therapeutics immuno-oncology subsidiary, BioXcel Therapeutics is collaborating with Dr. Louis M. Weiner, director of the Lombardi Comprehensive Cancer Center, and Dr. Benjamin Weinberg, principal investigator of the study.
  • BioXcel Therapeutics and Merck & Co. are providing BXCL701 and KEYTRUDA for the trial, respectively.

Dobson family gift to Driscoll marks new era for nationally recognized heart program

Retrieved on: 
Wednesday, April 24, 2024
Society, Interview, Laboratory, Hospital, Dobson, Risk, Cardiology, Survival, Heart, Christi, O'Driscoll (surname), Family, Patient, Operating, Electrophysiology, Growth, Cardiac catheterization, Pavilion

Corpus Christi, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Driscoll Children’s Hospital is celebrating a multimillion dollar gift by the Dobson Family Foundations, Las Aguilas Enterprises, and individual Dobson family members to support its Heart Center, a nationally recognized pediatric cardiac program that treats children and newborns with the most complex congenital heart diseases.

Key Points: 
  • Corpus Christi, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Driscoll Children’s Hospital is celebrating a multimillion dollar gift by the Dobson Family Foundations, Las Aguilas Enterprises, and individual Dobson family members to support its Heart Center, a nationally recognized pediatric cardiac program that treats children and newborns with the most complex congenital heart diseases.
  • Furthermore, the historic gift will establish the Harmon and Grace Dobson Distinguished Chair in Cardiac Surgery, the first of its kind at Driscoll and in South Texas.
  • In honor of the Dobson family’s everlasting gift, the fourth floor of the Pavilion will be named the Dobson Family Cardiac Suite.
  • Driscoll is grateful to the Dobson family for their faith in and commitment to our mission,” said Driscoll President and CEO Eric Hamon.

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Retrieved on: 
Wednesday, April 24, 2024
Carcinoma, Pembrolizumab, ASCO, Society, Annual general meeting, Bladder cancer, Pharmaceutical industry

IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that an abstract with final results of CORE-001, its Phase 2 trial of cretostimogene in combination with pembrolizumab, will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, which will take place from May 31-June 4, 2024, at McCormick Place Convention Center, in Chicago, IL.

Key Points: 
  • IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that an abstract with final results of CORE-001, its Phase 2 trial of cretostimogene in combination with pembrolizumab, will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, which will take place from May 31-June 4, 2024, at McCormick Place Convention Center, in Chicago, IL.
  • “We are delighted to be sharing the final results from our CORE-001 Phase 2 trial at ASCO, in line with the guidance we previously gave of providing additional CORE-001 durability data in 1H 2024,” said Vijay Kasturi, M.D., Chief Medical Officer, CG Oncology.
  • “In anticipation of sharing the final results from this trial, we would like to extend our heartfelt thanks to the investigators and patients who contributed to the trial’s success.”
    Details of the abstract are as follows:
    Final results of CORE-001 trial of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Retrieved on: 
Wednesday, April 24, 2024
EFS, PIN, Conference call, Myelodysplastic syndrome, Conference, Webcast, ASCO, SCT, Society, Data analysis, Annual general meeting, Therapy, ALL, BST

LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) was selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago).

Key Points: 
  • LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) was selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago).
  • Title: Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX Phase Ib/II study
    Session Title: Oral Abstract Session – Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
    A conference call and webcast to discuss the presented data will be held at 9:30 am EDT/2:30 pm BST on Saturday June 1, 2024.
  • Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
  • A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Cetuximab, ASCO, ALX, Pembrolizumab, Abstract, CD47, Patient, SAN, Publication, Society, Book

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31-June 4, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31-June 4, 2024.
  • Session titles and information for the two abstracts are listed below and are now available on the ASCO online program planner.
  • Evorpacept plus enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma: Phase 1a dose escalation results
    Results of a Phase 2 study of evorpacept (ALX148), and cetuximab, and pembrolizumab in patients with refractory microsatellite stable metastatic colorectal cancer
    Copies of the presentations will be available on the Publications section of ALX Oncology’s website following presentation at the meeting.

Carl Bolch, Jr. Appointed Chairman Emeritus After More Than Five Decades of Distinguished Service to RaceTrac, Inc.

Retrieved on: 
Wednesday, April 24, 2024
Society, Teaching, News, Research, National Association, RaceTrac, Convenience, Family, CSP, MJFF, Growth, Management

Atlanta, April 24, 2024 (GLOBE NEWSWIRE) -- After 56 years of company leadership as chairman of the board, the RaceTrac, Inc. board of directors unanimously voted Carl Bolch, Jr. into the role of chairman emeritus.

Key Points: 
  • Atlanta, April 24, 2024 (GLOBE NEWSWIRE) -- After 56 years of company leadership as chairman of the board, the RaceTrac, Inc. board of directors unanimously voted Carl Bolch, Jr. into the role of chairman emeritus.
  • During the same board of directors’ vote, current CEO of RaceTrac, Inc., Natalie Morhous, was appointed chairman of the board.
  • He grew the RaceTrac® and RaceWay® brands from 100 stores in two states to more than 800 stores across 13 states.
  • “It is impossible to summarize the indelible mark Carl has made on RaceTrac, the fuel and convenience store industries and society as a whole.

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
School, OTCQB, Abstract, TSX, MD, Doctor of Philosophy, GBM, ASCO, Duke University, Rated R, Patient, Society, MBA, Annual general meeting, MDNA, University Challenge 2013–14, Pharmaceutical industry

TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) --  Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of Clinical Oncology ("ASCO") to be held in Chicago from May 31 – June 4, 2024.

Key Points: 
  • TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) --  Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of Clinical Oncology ("ASCO") to be held in Chicago from May 31 – June 4, 2024.
  • The oral podium presentation will include new clinical data from the ongoing Phase 1/2 ABILITY-1 Study evaluating MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist, as both a monotherapy and in combination with pembrolizumab (KEYTRUDA®) in patients with advanced or metastatic solid tumors.
  • Details of the podium presentation are as follows:
    Title: “Results from ABILITY-1 Monotherapy Dose Escalation Study with MDNA11, an Engineered Long-acting IL-2 agonist, in patients with advanced solid tumors”
    Details of the poster presentation are as follows:
    Title: "Phase 2 Study of Bizaxofusp, an IL-4R Targeted Toxin Payload, in Nonresectable Recurrent GBM: Comparison of Overall Survival with Contemporaneous Eligibility-Matched and Propensity Score Balanced External Control Arm"
    Presenter: Dr. John Sampson, MD, PhD, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery, School of Medicine, Duke University, Durham, North Carolina, USA
    The full text of the published abstracts will be available on the 2024 ASCO Annual Meeting website on May 23rd, 2024 at 5:00 PM EDT.

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

Retrieved on: 
Wednesday, April 24, 2024
FDA, Food, Partnership, IND, ASCO, Arenavirus, Patient, Society, Annual general meeting, Cancer, Pharmaceutical industry

This program has the potential to benefit more patients than single mutation inhibitors.

Key Points: 
  • This program has the potential to benefit more patients than single mutation inhibitors.
  • The Company will publish preclinical data in an abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting.
  • Our HB-700 program targets five KRAS-mutations found in multiple cancer indications with a single product candidate,” said Joern Aldag, Chief Executive Officer at HOOKIPA.
  • We continue to define our clinical development strategy which includes the possibility of collaboration or partnership for this program.”